Monoclonal Antibodies Global Market To Reach Value Of About $180 Billion In 2025

12 Oct, 2021

The monoclonal antibodies (MAbs) market consists of sales of monoclonal antibodies and related services. Monoclonal antibodies are used to enhance and suppress the immune response in various medical conditions and to treat various diseases such as cancer, cardiovascular and cerebrovascular diseases. This industry includes establishments that produce anti-cancer monoclonal antibodies to prevent metastasis by reducing cell proliferation, immunological monoclonal anti-bodies, neuropharmacological monoclonal anti-bodies, anti-infective monoclonal antibodies, and other MAbs for human beings and animals.

Global Monoclonal Antibodies (MAbs) Market Size And Drivers:

The global monoclonal antibodies market size is expected to grow from $106.87 billion in 2020 to $114.43 billion in 2021 at a compound annual growth rate (CAGR) of 7.1%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The MAbs market size is expected to reach $179.56 billion in 2025 at a CAGR of 11.9%. The Increasing prevalence of cost-efficient biosimilar monoclonal antibodies are driving the monoclonal antibodies market growth.

Request For A Sample For The Global Monoclonal Antibodies (MAbs) Market Report:

Trends In The Global Monoclonal Antibodies (MAbs) Market

The monoclonal antibodies market has been witnessing multiple strategic initiatives in recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden products and services. Strategic collaborations or acquisitions and partnership agreements help vendors expand their existing product portfolio and geographical reach. For instance, In February 2019, AbCellera and Novartis enter into a multi-target partnership to create an antibody-drug discovery platform and technology for treating clinically-relevant and neurodegenerative diseases. Furthermore, AbCellera collaborated with GlaxoSmithKline (GSK), a pharmaceutical company, for the discovery of monoclonal antibodies against an undisclosed membrane protein target. Merck completed the acquisition of Sigma-Aldrich Corp., a leading life science company. Post this acquisition, Merck has more than 50,000 employees, 72 manufacturing sites, and a presence in 67 countries worldwide. Companies in the industry are increasingly realigning their portfolios and pursue profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favorable interest rates globally.

Global Monoclonal Antibodies (MAbs) Market Segments:
The global monoclonal antibodies market is further segmented –
By Source: Murine, Chimeric, Humanized, Human
By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular, Others
By End Users: Hospitals, Private Clinics, Research Institute
By Geography: The global MAbs market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Read More On The Report For The Global Monoclonal Antibodies (MAbs) Market At:

Monoclonal Antibodies (MAbs) Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides monoclonal antibodies market overviews, analyzes and forecasts market size and growth for the global monoclonal antibodies (MAbs) market, monoclonal antibodies (MAbs) market share, monoclonal antibodies (MAbs) market players, monoclonal antibodies (MAbs) market segments and geographies, monoclonal antibodies (MAbs) market’s leading competitors’ revenues, profiles and market shares. The monoclonal antibodies (MAbs) market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches

Call Us

+1 3156230293


+44 2071930708


+91 8897263534

(Asia & Others)